Last reviewed · How we verify

NCT03459352

Digital Symptom Tracking, Patient Engagement and Quality of Life in GI Oncology Clinic Patients

Completed NA Last updated 26 August 2020
What this trial tests

NA trial testing ePRO in Cancer in 38 participants. Completed in 4 April 2020.

Timeline
18 June 2018
Primary endpoint
4 April 2020
4 April 2020

Quick facts

Lead sponsorDuke University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposehealth services research
Enrollment38
Start date18 June 2018
Primary completion4 April 2020
Estimated completion4 April 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Duke University

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A pilot study of an ePRO system in cancer patients receiving systemic therapies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Duke University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03459352.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing